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EgyptIt was generally believed that Cystic ﬁbrosis (CF) is rare among Arabs; however, the few studies
available from Egypt and other Arabic countries suggested the presence of many undiagnosed
patients. The aim of the present study was to determine the frequency of CF patients out of the
referred cases in a single referral hospital in Egypt. A total of 100 patients clinically suspected of
having CF were recruited from the CF clinic of the Allergy and Pulmonology Unit, Children’s
Hospital, Cairo University, Egypt, throughout a 2 year period. Sweat chloride testing was done
for all patients using the Wescor macroduct system for collection of sweat. Quantitative analysis
for chloride was then done by the thiocyanate colorimetric method. Patients positive for sweat
chloride (P60 mmol/L) were tested for the DF508 mutation using primer speciﬁc PCR for cystic
ﬁbrosis transmembrane conductance regulator (CFTR) gene. Thirty-six patients (36%) had a
positive sweat chloride test. The main clinical presentations in patients were chronic cough in
32 (88.9%), failure to thrive in 27 (75%), steatorrhea in 24 (66.7%), and hepatobiliary involve-
ment in 5 (13.9%). Positive consanguinity was reported in 50% of CF patients. Thirty-two
patients were screened for DF508 mutation. Positive DF508 mutation was detected in 22
(68.8%) patients, 8 (25%) were homozygous, 14 (43.8%) were heterozygous, and 10 (31.3%)
tested were negative. CF was diagnosed in more than third of patients suspected of having
the disease on clinical grounds. This high frequency of CF among referred patients indicates
that a high index of suspicion and an increasing availability of diagnostic tests lead to the iden-
tiﬁcation of a higher number of affected individuals.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
CF is the most common potentially lethal and life-shortening
genetic diseases among populations of white Caucasian des-cent, such as those of Europe, North America, and Australia,
being caused by mutations of the (CFTR) gene [1]. The inci-
dence of CF varies according to the ethnic origin, ranging from
one in 2000 to one in 3500 Caucasians born in Europe, the
United States, and Canada [2].
Although extensively studied, the pathophysiology of CF
remains a challenge for scientists and clinicians. Clearly, the
detection of the causative gene (CFTR) and its predominant
mutation (delta F508) was a milestone in the CF research.
Since then, more than 1800 other mutations in the CFTR
genes were detected [3].
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different parts of the body, and certain organs seem to be more
sensitive than others [4]. Although CFTR expression is found
in the airway, salivary glands, pancreas, liver, sweat ducts, and
reproductive tract, it is the impact on the lungs and the gastro-
intestinal tract that has the major consequence for morbidity
and mortality [5,6]. Early diagnosis and advances in the care
of CF patients has improved survival, and as a result, patients
with the disease often live beyond the third decade [7,8].
Limited data are available regarding CF prevalence among
Egyptian children. CF has been believed to occur infrequently
in Egypt; only few papers suggested its presence [9,10]. The
clinical expression of the disease and the degree of involvement
of different systems (respiratory, gastrointestinal, reproduc-
tive, etc.) may vary in different populations and in children
of variable racial decent.
Therefore, the aim of the present study was to detect the
frequency of patients diagnosed as CF among patients clini-
cally suspected of having the disease and referred to Allergy
and Pulmonology Unit, Children’s Hospital, Cairo University,
Egypt, through a period of 2 years and to detect the frequency
of Delta F508 mutation among those diagnosed as CF.
Patients and methods
This is a longitudinal study recruiting patients clinically
suspected of having CF and referred to the CF clinic of the
Allergy and Pulmonology Unit, Children’s Hospital, Cairo
University, Egypt, throughout a 2 year period from February
2010 to February 2012. The study was approved by the scientiﬁc
research committee of the Pediatric Department, Faculty of
Medicine, Cairo University and a written consent was obtained
from all parents after they were fully informed of the details.
Patients included in this study had manifestations that sug-
gested the diagnosis of CF such as respiratory manifestations,
including chronic productive cough, bronchiectasis, recurrent
pneumonia, hemoptysis, recurrent sinusitis, nasal polyps, clubbing,
and/or gastrointestinal manifestations as meconium ileus in neo-
nates, malabsorption, steatorrhea, and/or failure to thrive or
short stature.
Sweat chloride test was done for all patients included in the
study using the standard pilocarpine iontophoresis for sweat
induction and the Wescor macroduct system for sweat collec-
tion as recommended by the NCCLS and cystic ﬁbrosis Foun-
dation (CFF) guidelines [11,12], followed by quantitative
analysis of the collected sample. Sweat test was repeated for
those who had a positive or equivocal sweat test results. The
delta F 508 mutation was done for patients who had positive
sweat test results.
Other routine investigations were done including complete
blood picture, stool analysis, sputum culture, plain x-ray,
and computerized tomography of the chest. The non-CF pa-
tients were further investigated to reach ﬁnal diagnosis as fol-
lows: bronchopulmonary dysplasia, immotile cilia syndrome,
alpha-1-antitrypsin deﬁciency, immunodeﬁciency, tuberculosis
and congenital bronchiectasis, celiac disease, and food allergic
enteropathy.
Quantitative sweat chloride testing
Sweat stimulation was done using the pilocarpine iontophore-
sis and sweat collection by the Wescor macroduct sweatcollection system [11]. The sweat sample was analyzed quanti-
tatively by the thiocyanate colorimetric method. The average
total volume of sweat sample is 20–50 ul. The Chloride was
assayed colorimetrically based upon the competition of Hg2+
and Fe2+ for thiocyanate. The preferred Hg-thiocyanate
adduct exhibits no color. In the presence of chloride, Hg2+ forms
mercuric chloride freeing up thiocyanate, which then binds to
the available Fe2+ exhibiting an absorbance at 450 nm. The
intensity of the color is directly proportional to the chloride
concentration in the sample. By using a Chloride standard
with known concentration (100 mmol/L), the intensity of the
color is converted to concentration according to Beer’s Law.
The Beer–Lambert law (or Beer’s law) is the linear relationship
between absorbance and concentration of an absorbing spe-
cies. The general Beer–Lambert law: A= a (k) \ b \ c, where
A is the measured absorbance, a(k) is a wavelength-dependent
absorptivity coefﬁcient, b is the path length, and c is the
analyte concentration. The intensity of the color formed is
proportional to the chloride ion concentration in the sample [12].
Reference values of quantitative chloride analysis are as fol-
lows: <40 mmol/L = negative, 40–60 mmol/L = borderline/
indeterminate, P60 mmol/L = positive and consistent with
the diagnosis of CF.
Molecular analysis
All patients with positive sweat chloride test were screened for
the presence of Delta F508 gene mutation as follows:
DNA extraction
DNA was extracted from whole blood samples using Qiagen
DNA extraction kit (QIAamp DNA mini kit; Qiagen, Hilden,
Germany) and following the manufacturers’ protocol.
PCR ampliﬁcation
Screening for Delta F508 mutation was performed by Allele
Speciﬁc Polymerase Chain Reaction (ASPCR) as previously
described by Schwarz and Malone [13]. The following
primers were used to detect the delta F508 mutation: forward
normal,-50-ggcaccattaaagaaaatatcatctt-30, forward mutant-
50-ggcaccattaaagaaaatatcattgg-30, and common reverse 50-
gttggcatgctttgatgacgcttc-30. The PCR components were as
follows: 10· Buffer without MgCl2, 50 mM MgCl2, 25 mM
dNTPs, 5U/ul Dream Taq DNA polymerase (MBI Fermentas,
Vilnius, Lithuania), 50–100 ng DNA, and 0.4 mM of each of
the primers.
PCR reactions were performed using the thermal cycler
PCR Express (Thermo Hybaid, Middlesex, UK). The ﬁnal
PCR volume was 25 ul. The ampliﬁcation conditions were as
follows: initial denaturation at 94 C for 1 min (1 cycle) fol-
lowed by 30 ampliﬁcation cycles, denaturation at 94 C for
1 min, annealing at 60 C for 45 s, and extension at 72 C for
1 min, with a ﬁnal extension step at 72 C for 6 min.
Ten microliters of ampliﬁcation products were analyzed by
means of vertical electrophoresis in 8% polyacrylamide gels
for 90 min (120 V) using the Bio-Rad Mini-Protean tetra gel
system (Bio-Rad, Hercules, CA, USA).
DNA samples of non-carrier subjects (having 2 wild-type
alleles) yielded a unique 98 base-pair (bp) fragment, whereas
Table 2 Demographic data of CF patients.
Variables N (%)
Age
Range 2 month–16 years
Mean ± SD 3.91 ± 4.18 years
Gender
Male 22 (61.1%)
Female 14 (38.9%)
Male:female ratio 1.6:1
Positive family history of CF 6 (16.7%)
Positive consanguinity 18 (50%)
Residence
Greater Cairo 22 (61.1%)
Delta 10 (27.8%)
Upper Egypt 4 (11.1%)
Proﬁle of cystic ﬁbrosis 565samples from heterozygous patients had 2 ampliﬁed fragments,
1 of 98 bp and 1 of 95 bp (lacking 3 base pairs), and ﬁnally,
DNA from homozygous individuals had only 1 ampliﬁed frag-
ment of 95 bp.
Statistical analysis
Results were analyzed using the Statistical Package for the So-
cial Sciences program (SPSS) version 13.0.1 and the statistical
program KyPlot version 3.0.2 h. Data were summarized using
mean, standard deviation (SD) and range for quantitative vari-
ables and number and percent for qualitative variables.
Results
The present study enrolled 100 Egyptian children with clinical
symptoms and signs suggestive of CF. Patient’s age ranged from
2 months to 16 years with a mean age of 3.65 ± 3.87 years.
Sixty-one of them were males and 39 were females. Basic
demographic and clinical data of all patients included in this
study are shown in Table 1, where the main clinical presenta-
tions of the study population were chronic cough in 84% of
cases, failure to thrive in 56%, steatorrhea in 37%, and less fre-
quently other presentations as clubbing, hepatobiliary system
affection, sinusitis, and nasal polyps. Calculated sensitivity
and speciﬁcity indicate the common clinical presentations of
the referred population consistent with the diagnosis of CF.
Average age at diagnosis was 3.9 years. 22 (61.1%) of them
were boys and 14 (38.9%) were girls. Being referral hospital,
Patients came from various parts of Egypt, and Consanguinity
was positive in 18 (50%) patients. History of deﬁnite CF in the
family was present in 6 patients (16.7%). Basic demographic
data of CF patients are shown in Table 2.
The main clinical presentations were chronic cough in 32
(88.9%), failure to thrive in 27 (75%), and steatorrhea in 24
(66.7%) patients. Details of clinical proﬁle of CF patients
are shown in Table 3.
The sweat chloride test was positive in 36 patients. The
mean value of sweat chloride test in CF patients was
86.8 ± 14.7 mmol/L (mean ± SD). Delta F508 mutation
could be identiﬁed in 22 (61.1%) patients, 8 (22.2%) patients
were homozygous, 14 (38.9%) were heterozygous, 10 patients
were negative, and the test was not done for 4 (11.1%) patients
as shown in Table 4.Table 1 Demographic data and clinical presentations of the study
Characteristics All study population N= 100
Age in years (Mean ± SD) 3.65 ± 3.87
Gender
Male 61 (61%)
Female 39 (39%)
Consanguinity 53 (53%)
Failure to thrive 56 (56%)
Chronic cough 84 (84%)
Hemoptysis 6 (6%)
Nasal Polyps 12 (12%)
Sinusitis 12 (12%)
Steatorrhea 37 (37%)
Hepatobiliary System aﬀection 17 (17%)
Meconium ileus 2 (2%)
Clubbing 26 (26%)At the time of presentation, Pseudomonas was the most fre-
quent organism cultured from respiratory secretions in 8
(22.2%) patients, and details of sputum culture, CT chest ﬁnd-
ing, and stool analysis are shown in Table 4.
Discussion
In developing countries, CF had remained largely unrecog-
nized. Its clinical features individually resemble those of other
diseases such as pneumonia, bronchiectasis, asthma, failure to
thrive, and celiac disease. Respiratory and gastrointestinal
problems associated with malnutrition and a high infant mor-
tality rate are very common in developing countries, and the
diagnosis of CF can therefore be missed due to a low index
of suspicion. If clinicians believe that CF is absent from their
population, they will not consider it in a differential diagnosis
[14].
The present study showed a high frequency of CF (36%) of
patients referred to our hospital suspected clinically of having
the disease. This high frequency compared to other studies
from Egypt probably indicates that the better awareness of
CF and the increasing availability of diagnostic tests (the sweat
test and/or DNA tests) frequently lead to the identiﬁcation of a
higher number of affected individuals [14]. More than 98% CFpopulation.
CF patients N = 36 Sensitivity Speciﬁcity
3.91 ± 4.18 – –
22 (61%) 61.11% 39.06%
14 (39%) 38.89% 60.94%
18 (50%) 50% 45.31%
27 (75%) 75% 54.69%
32 (88.9%) 88.89% 18.75%
3 (8.3%) 8.33% 95.31%
4 (11.1%) 11.11% 87.50%
3 (8.3%) 8.33% 85.94%
24 (66.7%) 66.67% 79.69%
5 (13.9%) 13.89% 81.25%
1 (2.8%) 2.78% 98.44%
11 (30.6%) 30.56% 76.56%
Table 3 Clinical characteristics of CF patients.
Variables (N= 36) No. (%)
Onset of diagnosis
During 1st year 12 (33.33%)
From 2–5 years 14 (38.89%)
After 5 years 10 (27.78%)
Onset of symptoms
Neonatal period 15 (41.67%)
Infancy 16 (44.44%)
From 2–5 years 3 (8.33%)
After 5 years 2 (5.56%)
History
Chronic cough 32 (88.9%)
Failure to thrive 27 (75%)
Appetite (good) 26 (72.2%)
Steatorrhea 24 (66.7%)
Hepatobiliary system aﬀection 5 (13.9%)
Hemoptysis 3 (8.3%)
Sinuses involvement 3 (8.3%)
Meconium ileus 1 (2.85)
History of recurrent hospital admission 28 (77.8%)
History of ICU admission 22 (61.1%)
General examination
Ht below 3rd percentile 17 (47.2%)
Wt below 3rd percentile 23 (63.8%)
Pallor 12 (33.3%)
Clubbing 11 (30.5%)
Cyanosis 5 (13.8%)
Nasal polyps 4 (11.1%)
Chest examination
Diminished air entry 12 (33.3%)
Crepitation 28 (77.7%)
Wheezes 24 (66.6%)
Bronchial breathing 12 (33.3%)
Cardiac examination
Manifestations of pulmonary hypertension 2 (5.6%)
Abdominal examination
Abdominal distension 21 (58.3%)
Hepatomegaly 5 (13.8%)
Table 4 Summary of the laboratory and radiological Inves-
tigations done for CF patients.
Investigations No. (%)
Sweat chloride test results
(Mean ± SD) (n= 36)
86.8 ± 14.7 mmol/L
Gene analysis for aDF508 (n = 32)
Negative 10 (27.8%) (0.167  0.501)b
Heterozygous 14 (38.9%) (0.268  0.621)b
Homozygous 8 (22.2%) (0.121  0.437)b
CT chest results (n = 36)
Normal 4 (11.1%)
Bronchiectasis and hyperinﬂation 11 (30.6%)
Consolidation 10 (27.8%)
Consolidation collapse and
hyperinﬂation
6 (16.7%)
Consolidation collapse 5 (13.8%)
Stool analysis for fat (n = 36)
Positive 26 (72.2%)
Negative 10 (27.8%)
Results of Sputum cultures (n = 36)
Pseudomonas aeruginosa 8 (22.22%)
Klebsiella pneumoniae 2 (5.55%)
Staphylococcus aureus 2 (5.55%)
Mixed ﬂora 2 (5.55%)
Candida 1 (2.77%)
E-coli 1 (2.77%)
Streptococci 1 (2.77%)
No growth 19 (52.82%)
a DF508: deletion of phenylalanine 508 of the cystic ﬁbrosis
transmembrane conductance regulator.
b 95% Conﬁdence intervals for the proportion.
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with a typical clinical picture, the usual problem is not inter-
preting the result, but remembering to ask for the test.
In Egypt, the ﬁrst study aiming at evaluating the magnitude
of the CF problem in Egypt was done by Abdel Salam and col-
leagues 1993 using the meconium BM-mec-test and reported a
prevalence rate of 1:2664 in 18,560 screened newborns and 1:56
in a series of 224 high risk children [9]. In another more recent
study done by Naguib and colleagues, 61 patients suspected of
having CF were screened using the CF Indicator sweat test sys-
tem (PolyChrome Medical, Inc., Brooklyn Center, MN) for
qualitative assessment of the sweat chloride concentration.
Of the 61 patients, 12 (20%) had positive sweat chloride
screening. Ten of the 12 patients underwent quantitative sweat
testing and were positive [10].
Some reports have been published about CF patients in the
Middle East [9,10] [16–28]. These reports showed the following
frequencies, 1:5800 in Bahrain [19], 1:2650 in Jordan, 1:2560 in
Kuwait [20], and 1: 15,876 in United Arab Emirates [21].Though CF was generally believed to be rare or nonexistent
in Saudi Arabia, in one study, 21 Saudi children were diag-
nosed as having CF, evidenced by typical clinical features
and elevated sweat chloride concentrations from seven referral
centers over a period of 10 years [22].
The few studies available about CF in Arabs are suspecting
the presence of many undiagnosed patients and emphasize a
higher incidence rate particularly in view of the high consan-
guinity rate in the range of 25–60% [24].
Furthermore, the population of the region is characterized
by large family size, high fertility rates, high maternal and
paternal age, and high rate of marriage among members of
the same tribes. In Bahrain, Al Mahroos found consanguine-
ous marriage in 80% of his study cases [19], and in Lebanon,
Desgeorges et al. detected a 50% rate of consanguineous mar-
riage [25]. The present study also revealed a high rate of con-
sanguineous marriage of 53% for the study population and
50% for the CF population which is higher than the reported
rate for the general population in Egypt which is 37% [29];
however, the study done by Naguib et al. showed a higher rate
of consanguineous marriage reaching to 84% [10].
In the present study, 6 patients (16.7%) gave a positive fam-
ily history of CF, compared to the study done by Naguib et al.
where 23% of CF patients have suggestive family history [10].
In our patients’ population, males represent 70% of the
whole study population and 86.6% in the CF patients. This
ﬁnding could reﬂect a true increase in disease incidence in
males or may suggest more severe disease in females with early
demise which needs further studies to identify the cause. This
Proﬁle of cystic ﬁbrosis 567ﬁnding may also reﬂect greater concern and care for male off
springs which is deeply rooted in Arab traditions.
CF diagnosis was established in the present study by the
age of 1 year in 12 patients (33.33%). In the United States,
the majority of cases (71%) were diagnosed by the same age
[15]. Shaha and colleagues 2006 diagnosed 58.3% of their pa-
tients in the ﬁrst 6 months of life [30]. It is likely that a delayed
diagnosis contributes signiﬁcantly to the high prevalence of
malnutrition in CF patients [25] and could also lead to pro-
gressive pulmonary disease and a shortened life span [29].
Due to genetic and environmental differences among ethnic
groups, CF presentation may vary between populations. In the
present study, 32 (88.9%) patients had chronic or recurrent
respiratory disease, 27 (75%) had failure to thrive, and 24
(66.7%) had an abnormal stool pattern ‘‘steatorrhea’’ at the
time of diagnosis. These results are similar to those of Al Mah-
roos, who detected failure to thrive in 96% and progressive
lung disease in 84% of Bahraini patients [19]. These results
are also close to the study of Shaha et.al, with pulmonary
problems in 80.6% and failure to thrive in 83.9% of their Paki-
stani patients [30]. Different reports from the North American
CF Registry 2003 indicate that 40.3% of CF patients had fail-
ure to thrive, 48.8% had respiratory symptoms and abnormal
stools/steatorrhea at time of diagnosis [31]. These ﬁndings may
be inﬂuenced by a delay in diagnosis or indicate a more severe
disease presentation.
Clinical phenotypes reported in studies from other popula-
tions in the Middle East suggest a relatively high incidence of
hepatobiliary manifestations (jaundice, hepatomegaly, or cho-
lelithiasis) in CF patients. Hepatobiliary involvement was re-
ported in (4%) to (10.9%) of Middle Eastern patients
diagnosed with CF [19,16]. In the study of Naguib et al., there
was only one patient with hepatobiliary involvement [10]. In
the present study, ﬁve of our patients (13.9%) had hepatobil-
iary manifestations; this frequency of hepatobiliary involve-
ment is much higher than that reported in the North
American CF Registry [31].
Analysis of the delta F508 mutations done in CF patients re-
vealed 8 (22.2%) patients with homozygous mutation.This is
close to the study done by Naguib et al. in which the delta F508
mutationwas detected in 25%of CFpatients [10]. This is in con-
trast to Caucasians where the major mutation F508 deletion is
found inabout70%ofCFalleles, but all othermutationsare rare
with a frequency ranging from 2% to less than 0.01% [32].
Fourteen patients (38.9%) with heterozygous mutation
were encountered and 10 (27.8%) were negative. Those pa-
tients had the classic phenotypic features of CF, so it is sug-
gested that other mutations rather than delta F508 could be
the underlying cause. Two known CF disease-producing muta-
tions (e.g., DF508), in the setting of an appropriate disease
phenotype, establish the diagnosis of CF; however, failure to
ﬁnd two CF disease-producing mutations cannot exclude the
diagnosis of CF. This may be explained by the fact that to
date, more than 1800 mutations have been reported, and of
these, only around 36 could be tested for by commercially
available panels in Egypt. Searching for the remaining muta-
tions requires complete sequencing and referral to specialized
labs. In addition, there are mutations that appear to be more
widely spread throughout the Middle East but are rarely ob-
served elsewhere. In some cases, these more frequent muta-
tions may be speciﬁc for a subset of the people in the Middle
East deﬁned by a common ethnic or religious background,e.g., the 1548delG mutation in Saudi Arabia [18,26], Bedouin
tribes in the case of I1234V [27], the S549R (T > G) mutation
in Bedouins from the United Arab Emirates and Oman [21],
and the 548A > T mutation in Bahrain [28].
Although these studies are diverse and the populations
examined were quite small in number, they suggest that the
CF problem in the Arab region and Egypt has been underesti-
mated and requires further investigation. To shed light on the
actual magnitude of the CF problem in Egypt, further large
nationwide screening studies are required.
Conclusions
This study showed a high prevalence of CF among suspected
patients, which is more than expected for our population from
previous studies. Quantitative Sweat chloride testing is a cru-
cial step in the work up done for patients with clinical suspect
of CF. It may be complemented with gene analysis especially in
patients with typical clinical picture and equivocal or negative
sweat chloride test. The spectrum and distribution of CFTR
mutations in Egypt could be deﬁned by screening the complete
CFTR gene in CF patients. This will allow a suitable mutation
panel to be set up for the Egyptian patients.
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